Join to View Full Profile
275 Collier Road, NwSuite 450Atlanta, GA 30309
Phone+1 404-351-8873
Fax+1 404-355-6165
Dr. Hengel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Emory University School of MedicineFellowship, Infectious Disease, 1994 - 1998
Cleveland Clinic FoundationResidency, Internal Medicine, 1991 - 1993
University of AlbertaClass of 1988
Certifications & Licensure
GA State Medical License 1994 - 2027
DC State Medical License 1998 - 2006
OH State Medical License 1992 - 1994
American Board of Internal Medicine Infectious Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- CMS Meaningful Use Stage 1 Certification Solution Series EHR, e-MDs, 2011
Publications & Presentations
PubMed
- Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers.Claudia P Schroeder, Richard L Hengel, Ramesh V Nathan, Timothy E Ritter, Engels N Obi
Anaerobe. 2022-10-01 - 8 citationsRecurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life.Richard L Hengel, Claudia P Schroeder, Jinhee Jo, Timothy E Ritter, Ramesh V Nathan
Journal of Patient-Reported Outcomes. 2022-05-14 - 31 citationsReal-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study.Richard L Hengel, Timothy E. Ritter, Ramesh V Nathan, Lucinda J. Van Anglen, Claudia P. Schroeder
Open Forum Infectious Diseases. 2020-03-19
Press Mentions
Bezlotoxumab (Zinplava)for Prevention of Recurrent C. Difficile InfectionOctober 7th, 2018
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (Fecal Microbiota, Live – Jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. Difficile InfectionSeptember 24th, 2023
Professional Memberships
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
